Neoadjuvant chemotherapy (NAC) is one of the standard-of-care therapies for breast cancer (BC) with axillary lymph node (ALN) metastases. However, the response to this therapy varies depending on the ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

A phase II study of weekly carboplatin and nab-paclitaxel with trastuzumab or bevacizumab as neoadjuvant therapy for patients with early-stage nonmetastatic breast cancer. This is an ASCO Meeting ...

Sentinel lymph node biopsy has replaced traditional axillary dissection, minimizing lymphedema risk in breast cancer surgery. The procedure targets the first draining lymph nodes, reducing unnecessary ...

It is possible to leave most of the lymph nodes in the armpit, even if one or two of them have metastases larger than two millimeters. This is shown in a trial enrolling women from five countries. The ...

Lymphedema is a chronic swelling or edema in a limb caused by a build-up of lymph fluid. This happens when the lymphatic system is damaged in some way. One common cause of damage is surgery, ...

The intraoperative molecular tests (RD‑100i OSNA system and Metasin test) are used during breast cancer surgery to detect the presence of 1 or 2 biological markers that are associated with metastatic ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...